AMGN Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 6.9% compared to Amgen's net margin of 15.24%. Amgen's return on equity of 66.87% beat Johnson & Johnson's return on equity of 19.98%.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 3.35%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 8.82%. Given that Johnson & Johnson has higher upside potential than Amgen, analysts believe Johnson & Johnson is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.99%. Johnson & Johnson offers a yield of 3.19% to investors and pays a quarterly dividend of $1.24 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Amgen's net income of $627M is lower than Johnson & Johnson's net income of $3.4B. Notably, Amgen's price-to-earnings ratio is 40.49x while Johnson & Johnson's PE ratio is 26.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.94x versus 4.25x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 6.9% compared to Amgen's net margin of 32.59%. Amgen's return on equity of 66.87% beat Eli Lilly and's return on equity of 80.24%.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 3.35%. On the other hand Eli Lilly and has an analysts' consensus of $1,010.47 which suggests that it could grow by 23.5%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.509, suggesting its less volatile than the S&P 500 by 49.093%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.99%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Amgen pays 118.14% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $9.1B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Amgen's net income of $627M is lower than Eli Lilly and's net income of $4.4B. Notably, Amgen's price-to-earnings ratio is 40.49x while Eli Lilly and's PE ratio is 69.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.94x versus 16.42x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 6.9% compared to Amgen's net margin of 24.22%. Amgen's return on equity of 66.87% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 3.35%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $915.34 which suggests that it could grow by 46.52%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.437, suggesting its less volatile than the S&P 500 by 56.337%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.99%. Regeneron Pharmaceuticals offers a yield of 0.14% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Amgen's net income of $627M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Amgen's price-to-earnings ratio is 40.49x while Regeneron Pharmaceuticals's PE ratio is 16.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.94x versus 5.07x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of 6.9% compared to Amgen's net margin of --. Amgen's return on equity of 66.87% beat Viking Therapeutics's return on equity of --.

Amgen has a consensus price target of $315.95, signalling upside risk potential of 3.35%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 286.66%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

Amgen has a beta of 0.583, which suggesting that the stock is 41.682% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.838, suggesting its less volatile than the S&P 500 by 16.205%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 2.99%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $9.1B, which are larger than Viking Therapeutics quarterly revenues of --. Amgen's net income of $627M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Amgen's price-to-earnings ratio is 40.49x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.94x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.